Pharmacokinetics (PK) of Trastuzumab-DM1 (T-DM1) and Paclitaxel (T) in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer (MBC) Previously Treated with a Trastuzumab-Containing Regimen

被引：0
|
作者：
Lu, D.
Krop, I.
Modi, S.
Elias, A.
LoRusso, P.
Huang, J.
Lu, M.
Girish, S.
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Colorado, Sch Med, Aurora, CO USA
[5] Wayne State Univ, Detroit, MI USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P3-14-22
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-22
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Francis W. Hunter
    Hilary R. Barker
    Barbara Lipert
    Françoise Rothé
    Géraldine Gebhart
    Martine J. Piccart-Gebhart
    Christos Sotiriou
    Stephen M. F. Jamieson
    British Journal of Cancer, 2020, 122 : 603 - 612
  • [22] A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+breast cancer
    Krop, I. E.
    Mita, M.
    Burris, H. A.
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Modi, S.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [23] Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
    Matsui, K.
    Yoshikawa, A.
    Oyama, K.
    Nozaki, Z.
    Tanada, Y.
    Earashi, M.
    Kiyohara, K.
    Nagata, T.
    Fukushima, W.
    Shimizu, T.
    Maeda, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (MBC) previously treated with pertuzumab (P).
    Urruticoechea, Ander
    Im, Seock-Ah
    Munoz, Montserrat
    Baselga, Jose
    Yardley, Denise A.
    Heeson, Sarah
    Jones, Sarah
    Knott, Adam
    Douthwaite, Hannah
    Crnjevic, Tanja Badovinac
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] T-DM1 for HER2-positive metastatic breast cancer
    Yaqub, Farhat
    LANCET ONCOLOGY, 2013, 14 (03): : E94 - E94
  • [26] Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
    Neelima Denduluri
    Janet L. Espirito
    Michelle D. Hackshaw
    Chuck Wentworth
    Tamy Recchia
    Winghan J. Kwong
    Drugs - Real World Outcomes, 2023, 10 : 177 - 186
  • [27] Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
    Denduluri, Neelima
    Espirito, Janet L.
    Hackshaw, Michelle D.
    Wentworth, Chuck
    Recchia, Tamy
    Kwong, Winghan J.
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 177 - 186
  • [28] Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
    Chunze Li
    Bei Wang
    Dan Lu
    Jin Y. Jin
    Yuying Gao
    Kiyoshi Matsunaga
    Yuriko Igawa
    Ihsan Nijem
    Michael Lu
    Alexander Strasak
    Nataliya Chernyukhin
    Sandhya Girish
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 547 - 558
  • [29] Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients
    Kowalczyk, Lidia
    Bartsch, Rupert
    Singer, Christian F.
    Farr, Alex
    BREAST CARE, 2017, 12 (06) : 401 - 408
  • [30] Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1)
    Krop, I. E.
    Burris, H. A.
    Rugo, H.
    O'Shaughnessy, J.
    Vogel, C. L.
    Amler, L.
    Strauss, A.
    Wong, E. K.
    Klencke, B.
    Pippen, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345